<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680272</article-id><article-id pub-id-type="doi">10.3390/v16121924</article-id><article-id pub-id-type="publisher-id">viruses-16-01924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genetic Diversity and Epidemiology of Enteroviruses and Rhinoviruses in Children Hospitalized with Acute Respiratory Infections in Novosibirsk, Russia (2023&#x02013;2024)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7891-5847</contrib-id><name><surname>Nokhova</surname><given-names>Alina R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><name><surname>Saroyan</surname><given-names>Tereza A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role></contrib><contrib contrib-type="author"><name><surname>Solomatina</surname><given-names>Mariya V.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role></contrib><contrib contrib-type="author"><name><surname>Gutova</surname><given-names>Tatyana A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5984-0819</contrib-id><name><surname>Derko</surname><given-names>Anastasiya A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7780-1485</contrib-id><name><surname>Dubovitskiy</surname><given-names>Nikita A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><name><surname>Murashkina</surname><given-names>Tatyana A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name><surname>Sharshov</surname><given-names>Kirill A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Shestopalov</surname><given-names>Alexander M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role></contrib><contrib contrib-type="author"><name><surname>Kurskaya</surname><given-names>Olga G.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-viruses-16-01924" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Portella</surname><given-names>Giuseppe</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01924">Federal Research Center of Fundamental and Translational Medicine, Novosibirsk 630060, Russia; <email>alina.nokhova@gmail.com</email> (A.R.N.); <email>111.st.13@rambler.ru</email> (T.A.S.); <email>solomatina.mariyav@yandex.ru</email> (M.V.S.); <email>a.derko19@gmail.com</email> (A.A.D.); <email>nikitadubovitskiy@gmail.com</email> (N.A.D.); <email>tamurashkina@frcftm.ru</email> (T.A.M.); <email>sharshov@yandex.ru</email> (K.A.S.); <email>shestopalov2@mail.ru</email> (A.M.S.)</aff><author-notes><corresp id="c1-viruses-16-01924"><label>*</label>Correspondence: <email>kurskaya_og@mail.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1924</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>02</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Rhinoviruses and respiratory enteroviruses remain among the leading causes of acute respiratory infections, particularly in children. Little is known about the genetic diversity of enteroviruses and rhinoviruses in pediatric patients with acute respiratory infections in Russia. We assessed the prevalence of human rhinoviruses/enteroviruses (HRV/EV) in 1992 children aged 0 to 17 years hospitalized with acute respiratory infections during the 2023&#x02013;2024 epidemic season using PCR. The detection rate of HRV/EV was 11% (220/1992). We performed typing of 58 HRV and 28 EV viruses by partial sequencing of the VP1 gene. Rhinovirus A was the most common among HRV, followed by rhinovirus C; rhinovirus B was detected in only three cases. Enteroviruses were represented by all four species, with the EV-D68 genotype being the most frequently detected. Phylogenetic analysis of the VP1 fragment of EV-D68 showed that all our sequences belonged to the B3 subclade. We identified the first case of EV-C105 infection in Russia in a two-year-old girl hospitalized with pneumonia. Phylogenetically, the Novosibirsk strain EV-C105 was closely related to a strain discovered in France in 2018. This research helped to fill a critical gap in understanding the epidemiological landscape of HRV/EV in pediatric populations within Russia.</p></abstract><kwd-group><kwd>enteroviruses</kwd><kwd>rhinoviruses</kwd><kwd><italic toggle="yes">Picornaviridae</italic></kwd><kwd>EV typing</kwd><kwd>EV-C105</kwd><kwd>EV-D68</kwd></kwd-group><funding-group><award-group><funding-source>RSF</funding-source><award-id>23-24-00492</award-id></award-group><funding-statement>This research was funded by RSF grant number 23-24-00492.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01924"><title>1. Introduction</title><p>Enteroviruses (EV) and Human Rhinoviruses (HRV) belong to the genus Enterovirus of the Picornaviridae family, which is classified into 15 species (EV A&#x02013;L and HRV A&#x02013;C). EV A&#x02013;D and HRV A&#x02013;C are pathogenic to humans [<xref rid="B1-viruses-16-01924" ref-type="bibr">1</xref>]. The HRV/EV genome is represented by a single-stranded positive-sense RNA, consisting of a 5&#x02019; untranslated region (UTR), an open reading frame (ORF) that encodes a single precursor polypeptide, and a 3&#x02019; untranslated region with a poly-A-tail. The precursor polypeptide undergoes post-translational processing, resulting in the formation of four structural proteins (VP1&#x02013;4) and seven non&#x02013;structural proteins. On the basis of amino acid sequence, divergence of the VP4/2 genes or VP1 genes EV and HRV are divided into more than 100 types [<xref rid="B2-viruses-16-01924" ref-type="bibr">2</xref>]. Despite their genetic similarity, rhinoviruses and enteroviruses cause a broad spectrum of diseases [<xref rid="B3-viruses-16-01924" ref-type="bibr">3</xref>]. Rhinoviruses are one of the main causes of acute respiratory tract infections [<xref rid="B4-viruses-16-01924" ref-type="bibr">4</xref>]. Most often, HRV causes mild self-limited diseases but can also lead to severe lower respiratory tract illnesses such as bronchiolitis and pneumonia, as well as exacerbations of bronchial asthma or chronic obstructive pulmonary disease [<xref rid="B5-viruses-16-01924" ref-type="bibr">5</xref>]. At the same time, EV can infect various tissues and can cause diseases of the gastrointestinal tract, respiratory, and nervous systems, such as hand-foot-and-mouth disease, viral meningitis, encephalitis, acute flaccid paralysis [<xref rid="B6-viruses-16-01924" ref-type="bibr">6</xref>]. Some EV genotypes are predominantly isolated from respiratory samples, e.g., enteroviruses EV-C104, EV-C105, EV-C109, EV-C117, EV-C118, CV-A21, EV-D68 [<xref rid="B3-viruses-16-01924" ref-type="bibr">3</xref>]. These genotypes cause respiratory tract diseases of varying severity and can, in some cases, lead to acute flaccid paralysis [<xref rid="B7-viruses-16-01924" ref-type="bibr">7</xref>]. Particularly, EV-D 68 caused a major outbreak of severe respiratory disease and neurological complications in children in 2014, affecting more than 2000 people worldwide, primarily children [<xref rid="B8-viruses-16-01924" ref-type="bibr">8</xref>]. Now, it continues to represent a global public health concern [<xref rid="B9-viruses-16-01924" ref-type="bibr">9</xref>].</p><p>Since 2020, the COVID-19 pandemic and associated disease control measures have significantly altered the circulation patterns of enveloped viruses, including the influenza virus, respiratory syncytial virus (RSV), and human metapneumovirus. Concurrently, studies have shown that the circulation of rhinoviruses and enteroviruses has remained stable, continuing to be an important component of the respiratory viral spectrum [<xref rid="B10-viruses-16-01924" ref-type="bibr">10</xref>]. However, little is known about the genetic diversity of enteroviruses and rhinoviruses in children with acute respiratory infections in Russia.</p><p>In this study, we assessed the contribution of enteroviruses to the etiology of acute respiratory infections in hospitalized children during the 2023&#x02013;2024 period. We examined age distribution, clinical signs of illness, and the genetic diversity of human rhinovirus (HRV) and enteroviruses (EV). This research aims to fill a critical gap in understanding the epidemiological landscape of these viruses in pediatric populations within Russia.</p></sec><sec id="sec2-viruses-16-01924"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01924"><title>2.1. Ethics Issues</title><p>The study was approved by the Committee on Biomedical Ethics at FRC FTM (protocol No. 16 of 15 June 2023). Each patient/legal representative involved in the study signed an informed consent.</p></sec><sec id="sec2dot2-viruses-16-01924"><title>2.2. Sample Collection</title><p>The study included 1992 children aged from 0 to 17 years hospitalized with acute respiratory infection (ARI) in two hospitals: Novosibirsk Children&#x02019;s Municipal Clinical Hospital No. 6, which provides medical care to approximately 2000 patients with ARI, bronchitis, and pneumonia annually, and Novosibirsk Children&#x02019;s Municipal Clinical Hospital No. 3, which provides medical care to 5000 patients with ARI, bronchitis, and pneumonia annually. The inclusion criteria were a duration of the disease of less than 7 days, the presence of at least one systemic symptom (fever, malaise, myalgia, headache), and one respiratory symptom (cough, sore throat, runny nose/nasal congestion, shortness of breath). On the first day after admission, a nasal and throat swab was taken from the child and placed in a tube with the transport medium (MEM medium, 0.5% bovine serum albumin, 100 mcg/mL gentamicin). The samples were stored at &#x02212;20 &#x000b0;C before delivery to the laboratory, but no more than 72 h. In addition, a questionnaire was filled out for each patient, which reflected the main demographic data (gender, age), clinical symptoms of the disease, the presence of chronic diseases, hospitalization in the ICU, and the clinical diagnosis.</p></sec><sec id="sec2dot3-viruses-16-01924"><title>2.3. Detection of Respiratory Viruses</title><p>Total RNA/DNA was isolated from respiratory samples using a commercial Ribosorb kit (Interlabservice, Moscow, Russia) in accordance with the manufacturer&#x02019;s instructions. Reverse transcription was performed using the Reverta-L kit (Interlabservice, Moscow, Russia) in accordance with the manufacturer&#x02019;s instructions.</p><p>The detection of influenza (HInfV) and SARS-CoV-2 viruses was performed using the AmpliPrime Influenza SARS-CoV-2/Flu(A/B/H1pdm09) PCR kit (NextBio, Moscow, Russia). Respiratory syncytial virus (HRSV); coronaviruses NL63/229E, OC43/HKU1 (HCoV); parainfluenza virus types 1&#x02013;4 (HPIV); metapneumovirus (HMPV); rhinovirus (HRV); adenovirus (HAdV); and bocavirus (HBoV) were detected using the AmpliSens ARVI-screen-FL PCR kit (Interlabservice, Moscow, Russia). The detection of enteroviruses was carried out using the AmpliSens Human enterovirus-FL PCR kit (Interlabservice, Moscow, Russia).</p></sec><sec id="sec2dot4-viruses-16-01924"><title>2.4. HRV/EV Typing</title><p>Nasal and throat swabs were suspended in 1000 &#x000b5;L of transport medium and centrifuged at 3000 rpm for 3 min. RNA extraction was carried out using the RNA Isolation Column Kit (modified) (Biolabmix, Novosibirsk, Russia) according to the manufacturer&#x02019;s recommendations and stored at &#x02212;80 &#x000b0;C until further analysis.</p><p>Sequencing of the VP1 capsid protein gene portion was performed in accordance with WHO recommendations [<xref rid="B11-viruses-16-01924" ref-type="bibr">11</xref>]. Extracted RNA was then reverse-transcribed into cDNA using a reverse transcriptase RNAscribe RT kit (Biolabmix, Novosibirsk, Russia) and a set of primers (<xref rid="viruses-16-01924-t001" ref-type="table">Table 1</xref>) for the VP1 gene (AN32, AN33, AN34, and AN35 in concentration 10 pmol/&#x003bc;L). Following incubation at 25 &#x000b0;C for 10 min, 55 &#x000b0;C for 50 min, and 85 &#x000b0;C for 5 min, the entire 20 &#x003bc;L RT reaction mixture was utilized for the first PCR (PCR1), which had a final volume of 50 &#x003bc;L. This reaction included primers SO224 and SO222 in a concentration 10 pmol/&#x003bc;L (Table) and was conducted using the BioMaster HS-Taq PCR-Color (2&#x000d7;) kit (Biolabmix, Novosibirsk, Russia) under the following conditions: 95 &#x000b0;C for 5 min, followed by 39 cycles of 95 &#x000b0;C for 20 s, 42 &#x000b0;C for 30 s, and a ramp of 0.4&#x000b0;C/s to 60 &#x000b0;C for 45 s, then 72 &#x000b0;C for 45 s, and a final extension at 72 &#x000b0;C for 5 min. Semi-nested PCR2 was conducted using 1 &#x003bc;L of the PCR1, primers AN88 and AN89 (10 pmol/&#x003bc;L) employing the BioMaster HS-Taq PCR-Color (2&#x000d7;) kit (Biolabmix, Novosibirsk, Russia) under the following conditions: at 95 &#x000b0;C for 5 min prior to 39 amplification cycles of 95 &#x000b0;C for 20 s, 60 &#x000b0;C for 20 s, and 72 &#x000b0;C for 15 s followed by a final incubation at 72 &#x000b0;C for 5 min. The result of PCR2 is a product of a VP1 gene fragment of 348&#x02013;393 bp. The reaction products were separated and visualized on 1.5% agarose gels with ethidium bromide (0.5 &#x003bc;g/mL). The appropriate size products were purified from the gel using the GeneJET Gel Extraction Kit (Thermo Fisher Scientific, Waltham, MA, USA). The resulting DNA templates were sequenced with a BigDye Terminator v3.1 ready reaction cycle sequencing kit on an ABI 3500xL Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientific, Foster City, CA, USA) by using primers AN89 and AN88. A total of 77 sequences of the partial VP1 203&#x02013;353 nt were deposited in GenBank (accession numbers rhinoviruses: PQ539483-PQ539537, accession numbers enteroviruses: PQ519611-PQ519632). Sequences obtained were compared with the enterovirus sequences available in NCBI GenBank.</p><p>Finally, we selected samples for further sequencing from HRV/EV positive cases with a PCR cycle threshold (Ct) value &#x02264; 25, totaling 111 out of 220 positive samples. From these, we chose those that had a concentration of 3 ng/&#x000b5;L or higher after elution for sequencing and subsequent typing. This process enabled us to reliably type 86 viruses. Of these, 78 viruses were subjected to phylogenetic analysis, as their sequence quality and length met the necessary criteria for analysis.</p></sec><sec id="sec2dot5-viruses-16-01924"><title>2.5. Phylogenetic Analysis</title><p>Sequences of fragments of the VP1 region of enteroviruses and rhinoviruses obtained from this study were compared against nucleotide sequences from the relevant taxonomy group downloaded from NCBI GenBank. All sequences were then aligned using the MAFFT-L-INS-i (v7.520) [<xref rid="B12-viruses-16-01924" ref-type="bibr">12</xref>]. Phylogenetic trees were constructed using the Maximum Likelihood (ML) method implemented in IQ-TREE IQtree v1.6.12 [<xref rid="B13-viruses-16-01924" ref-type="bibr">13</xref>]. An ultrafast bootstrap (UFBoot) [<xref rid="B14-viruses-16-01924" ref-type="bibr">14</xref>] and an approximate likelihood ratio test with the Shimodaira-Hasegawa-like (SH-aLRT) procedure [<xref rid="B15-viruses-16-01924" ref-type="bibr">15</xref>] were used to evaluate support for nodes on the tree for 1000 replicates. Visualization was done with iTOL [<xref rid="B16-viruses-16-01924" ref-type="bibr">16</xref>].</p></sec><sec id="sec2dot6-viruses-16-01924"><title>2.6. Statistical Analysis</title><p>Descriptive statistics were performed with median and interquartile range for quantitative variables, with absolute, relative frequencies and 95% confidence interval for categorical variables. The Manna-Whitney (U) test and the Chi-square test (Chi2) were applied to identify the statistical significance. Differences between groups were analyzed by the Kruskal-Wallis test (H) and multiple corrections were performed using Dunn&#x02019;s post hoc test with Bonferroni correction. To quantify effect size, we used risk ratio (RR) with 95% CI, as well as the adjusted standardized residual (AR). An adjusted standardized residual greater than 1.96 indicates a statistically significant difference from the expected frequencies. The relationship between age and the presence of EV/HRV was assessed with Spearman&#x02019;s rank correlation. The <italic toggle="yes">p</italic>-values were computed using permutation techniques with 999,999 iterations. The statistical significance was set to <italic toggle="yes">p</italic> &#x0003c; 0.05. The analysis was performed using R v.4.3.2, Python v.3.12, RStudio software, and GraphPad Prism v.10.3.1.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01924"><title>3. Results</title><p>The study was conducted from September 2023 to May 2024, coinciding with a seasonal increase in the incidence of acute respiratory infections. As part of the annual monitoring of respiratory viruses in hospitalized children, nasal and pharyngeal swabs were taken within 24 h of admission and subsequently analyzed by real-time PCR to detect common respiratory viruses. A total of 1992 samples were collected from children aged 0&#x02013;17 years. Of these, 1098 (55.1%) samples were obtained from boys and 894 (44.9%) samples were obtained from girls. The largest number of samples was obtained from infants. The gender and age distribution of the patients is presented in <xref rid="viruses-16-01924-t002" ref-type="table">Table 2</xref>.</p><sec id="sec3dot1-viruses-16-01924"><title>3.1. Detection of Respiratory Viruses</title><p>PCR testing revealed that at least one respiratory virus was detected in 1190/1992 (59.8%) of the included patients. Viral co-infection was detected in 171/1992 (8.6%) children. To identify age differences, we divided patients into the following age groups: children in the first year of life (0&#x02013;12 months), young children (1&#x02013;2 years), preschool children (3&#x02013;6 years), and school-age children (7&#x02013;17 years). The detection rate of respiratory viruses, as well as the frequency of viral co-infection, decreased with age being significantly lower in the age group of 7&#x02013;17-year age group compared with all other ages (<xref rid="viruses-16-01924-f001" ref-type="fig">Figure 1</xref>).</p><p>HRSV was the most prevalent in the etiology of ARIs during 2023&#x02013;2024, which was detected in 305/1992 (15.3%) children. HRSV was significantly more frequently detected in children under 12 months of age compared with all other age groups (AR = 5.67, <italic toggle="yes">p</italic> &#x0003c; 0.001), with detection rates of 23.4%, 15.2%, 12.3%, and 4.5% for the respective age groups. A similar pattern was observed for SARS-CoV-2, which was significantly more common in children aged 0&#x02013;12 months compared to children aged 1&#x02013;2 years old, 3&#x02013;6 years old, and 7&#x02013;17 years old (AR = 6.41, <italic toggle="yes">p</italic> &#x0003c; 0.001) with detection rates of 13.0%, 6.4%, 2.0%, and 2.6%, respectively. HInfV was found in 179/1992 (9.0%) children, with the detection rate increasing with age; it was significantly higher in preschool (AR = 3.60, <italic toggle="yes">p</italic> &#x0003c; 0.001) and school-age (AR = 6.83, <italic toggle="yes">p</italic> &#x0003c; 0.001) children compared to those aged children 0&#x02013;12 months and 1&#x02013;2 years old with rates 13.3%, 12.7%, 4.5%, and 8.8%, respectively. The incidence of respiratory viruses across different age groups is shown in <xref rid="viruses-16-01924-f002" ref-type="fig">Figure 2</xref>.</p></sec><sec id="sec3dot2-viruses-16-01924"><title>3.2. Detection of HRV/EV</title><p>HRV detection was carried out using the ARVI-screen-FL PCR kit (Interlabservice, Moscow, Russia) and EV detection was performed using the AmpliSens Human enterovirus-FL PCR kit (Interlabservice, Moscow, Russia). The limitation of these kits includes potential cross-reactivity and the identification of closely related variants of enteroviruses and rhinoviruses, as noted in the manufacturer&#x02019;s instructions. In our study, we found that out of 220 samples positive for HRV/EV by PCR, 121 samples were positive only for HRV, 49 samples were positive only for EV, and 50 samples detected both HRV and EV simultaneously.</p><p>There was no significant difference between sex and the presence of HRV/EV (<italic toggle="yes">p</italic> = 0.946). However, there was a statistically significant, negative, very weak correlation between age and the presence of HRV/EV (rs = &#x02212;0.070, <italic toggle="yes">p</italic> = 0.002). In children under 1 year of age, the risk ratio for EV infection was 1.35 (95% CI: 1.05 to 1.74) (<xref rid="viruses-16-01924-t003" ref-type="table">Table 3</xref>).</p><p>The prevalence of different respiratory viruses was not the same at different times of the year (Chi2 = 492.76, <italic toggle="yes">p</italic> &#x0003c; 0.001). HRV/EV were detected throughout the study period, with the peak infection rate in the autumn months (AR = 7.62, <italic toggle="yes">p</italic> &#x0003c; 0.001). During the winter months, there was a significant decrease in the detection levels of HRV/EV (AR = &#x02212;6.30, <italic toggle="yes">p</italic> &#x0003c; 0.001) attributed to the prevalence of HInfV (AR = 12.34, <italic toggle="yes">p</italic> &#x0003c; 0.001) and HRSV (AR = 7.37, <italic toggle="yes">p</italic> &#x0003c; 0.001) (<xref rid="viruses-16-01924-f003" ref-type="fig">Figure 3</xref> and <xref rid="viruses-16-01924-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec3dot3-viruses-16-01924"><title>3.3. Clinical Signs of HRV/EV Infections</title><p>We compared the clinical features of HRV/EV infection with those of Influenza and RSV infection. The distribution of various symptoms among children with respiratory viruses, HRV/EV, differs significantly (<italic toggle="yes">p</italic> = 0.020). However, the contribution to these differences is primarily due to the symptom distribution associated with HInfV and HRSV rather than HRV/EV (<xref rid="viruses-16-01924-t004" ref-type="table">Table 4</xref>). Malaise was significantly more common in children with HInfV (AR = 2.52) and less frequent in those with HRSV (AR = &#x02212;2.12) (<xref rid="viruses-16-01924-f005" ref-type="fig">Figure 5</xref>). Conversely, dyspnea was more frequently observed in children with HRSV (AR = 2.52) but less so in those with HInfV (AR = &#x02212;2.09) (<xref rid="viruses-16-01924-f005" ref-type="fig">Figure 5</xref>). Nasal congestion was significantly less common in children with HRSV (AR = &#x02212;2.69) (<xref rid="viruses-16-01924-f005" ref-type="fig">Figure 5</xref>). Statistically significant differences in temperature were found between HRV/EV, HInfV, and HRSV (<italic toggle="yes">p</italic> &#x0003c; 0.001). Post hoc comparisons revealed differences between all pairs: HRV/EV and HInfV (<italic toggle="yes">p</italic> &#x0003c; 0.001), HRV/EV and HRSV (<italic toggle="yes">p</italic> = 0.001), and HInfV and HRSV (<italic toggle="yes">p</italic> &#x0003c; 0.001). Statistically significant differences in the frequency of hypoxia were found between HRV/EV, HInfV, and HRSV (<italic toggle="yes">p</italic> = 0.015). Post hoc comparisons revealed differences between HRV/EV and HRSV (<italic toggle="yes">p</italic> = 0.030). No statistically significant differences in ICU admission were found (<italic toggle="yes">p</italic> = 0.177).</p></sec><sec id="sec3dot4-viruses-16-01924"><title>3.4. HRV/EV Typing and Phylogenetic Analysis</title><p>By partial sequencing of the VP1 gene, we performed typing of samples positive for HRV/EV. A total of 58 HRV and 28 EV samples were typed, including one rhinovirus sample and one enterovirus sample, which were collected during the 2022&#x02013;2023 epidemic season. Rhinoviruses A (32 samples, 15 genotypes) were the most common among HRV, followed by rhinoviruses C (23 samples, eight genotypes). Rhinoviruses B were detected in only three cases (three genotypes). Enteroviruses were represented by all four species, with enterovirus D being the most frequently detected (13 samples), all belonging to the EV-D68 genotype. Enteroviruses A were represented by the genotypes coxsackievirus A2 and coxsackievirus A6. Among enteroviruses B, we identified coxsackievirus B 5, echovirus 5, and echovirus 6. Enterovirus C was represented by a single sample EV-C105 from the 2022&#x02013;2023 season. The prevalence of HRV/EV genotypes is shown in <xref rid="viruses-16-01924-t005" ref-type="table">Table 5</xref>.</p><p>A comparison of the seasonal distribution of HRV and EV revealed that rhinoviruses were detected throughout the entire observation period (September 2023&#x02013;May 2024), while the vast majority of enteroviruses were detected in the fall of 2023 (<xref rid="viruses-16-01924-f006" ref-type="fig">Figure 6</xref>).</p><p>The sequences of 56 rhinoviruses identified in this study belonged to three different species and exhibited similarities with various strains collected worldwide (Europe, East Asia, America, Africa, and Australia) between 2003 and 2023 (<xref rid="viruses-16-01924-f007" ref-type="fig">Figure 7</xref>). Given the extensive development of international air travel, tracking patterns of transmission has become a challenging task.</p><p>A detailed comparative analysis of the nucleotide sequences of Novosibirsk isolates coxsackievirus A6 showed an appreciable level of similarity with strains detected in 2017 and 2023 in various cities of Russia (Khabarovsk, Miass) as well as other countries, such as China and The Netherlands (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>). Another genotype of EV, coxsackievirus A2, found in our study exhibited significant genetic similarity to a strain identified in the Russian city Yoshkar-Ola in 2019 (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>), which was isolated from a throat swab. The Novosibirsk strain of coxsackievirus B5 demonstrated a close similarity of the nucleotide sequence of VP1 with the strain from Novgorod, which circulated in 2023 (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>). Furthermore, we observed that the echovirus 6 strain had genetic similarities with those circulated in 2022. Two cases of echovirus 6 were detected in patients from Omsk and Yekaterinburg (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>), with biological material sourced from cerebrospinal fluid and feces. Outside the Russian Federation, this strain was found in throat swabs collected in Kazakhstan (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>).</p><p>It is especially important to emphasize that in our study, we detected a strain of EV-C105 for the first time in Russia, similar to the strain from France identified in a throat swab in 2018 (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>).</p><p>Additionally, our investigation revealed several sequences of EV-D68, the vast majority of which exhibited a high degree of genetic similarity to those collected from the nasopharyngeal swabs of children in Senegal (Africa) in 2023 (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>). Interestingly, one strain was closely related to a variant from Canada, sourced from a nasopharyngeal swab in 2022 (<xref rid="viruses-16-01924-f008" ref-type="fig">Figure 8</xref>). Phylogenetic analysis of the VP1 fragment showed that all our sequences belonged to the B3 subclade of enterovirus D68 (<xref rid="viruses-16-01924-f009" ref-type="fig">Figure 9</xref>).</p></sec><sec id="sec3dot5-viruses-16-01924"><title>3.5. Clinical Characteristics of HRV-A and HRV-C Infection</title><p>To examine previous reports on the differences in clinical characteristics (particularly severity) between HRV subtypes, we compared the clinical characteristics of diseases caused by HRV-A and HRV-C in order to identify the possible effect of the virus type on the disease severity. No statistically significant differences were found; however, a tendency toward statistically significant differences between HRV-A and HRV-C was found in age (<italic toggle="yes">p</italic> = 0.090), presence of hypoxia (<italic toggle="yes">p</italic> = 0.050), and diagnoses (<italic toggle="yes">p</italic> = 0.076, due to the low proportion of upper respiratory tract diseases in children with HRV-C) (<xref rid="viruses-16-01924-t006" ref-type="table">Table 6</xref>).</p></sec><sec id="sec3dot6-viruses-16-01924"><title>3.6. Clinical Characteristics of EV-D68 Infection</title><p>To verify the differences between our study and previous reports that EV-D68 causes neurological manifestations in addition to respiratory disease, we have analyzed the clinical characteristics of EV-D68 infection. In total, we have confirmed 13 cases of EV-D68 infection. Most of the patients were young children with a median age of 18 months. All children had no chronic diseases. All patients had a fever (median Temperature was 38.3 &#x000b0;C), 76.92% of patients had a cough, and 69.23% had shortness of breath. Almost half of the cases occurred with hypoxia, but none of the patients needed oxygen support, mechanical ventilation, or hospitalization in the ICU. All patients with EV-D68 had low respiratory tract infections, including acute bronchitis in 61.54% of cases, and pneumonia in 38.46% of cases. None of the patients exhibited neurological symptoms (<xref rid="viruses-16-01924-t007" ref-type="table">Table 7</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01924"><title>4. Discussion</title><p>Rhinoviruses and respiratory enteroviruses remain one of the leading causes of acute respiratory infections, especially in children [<xref rid="B3-viruses-16-01924" ref-type="bibr">3</xref>,<xref rid="B17-viruses-16-01924" ref-type="bibr">17</xref>]. In our study, we found that the HRV/EV ratio reached 18.5% (220/1190) among PCR-confirmed viral infections in hospitalized children in 2023&#x02013;2024 in Novosibirsk. Rhinoviruses are considered the primary cause of the so-called &#x0201c;common cold&#x0201d; with mild symptoms, but they can cause severe diseases of the lower respiratory tract, requiring hospitalization, such as bronchitis, bronchiolitis, and pneumonia [<xref rid="B5-viruses-16-01924" ref-type="bibr">5</xref>,<xref rid="B18-viruses-16-01924" ref-type="bibr">18</xref>]. In our study, 53.6% (118/220) of children with RV/EV had bronchitis and 29.5% (65/220) of the children had pneumonia.</p><p>Rhinoviruses and enteroviruses are heterogeneous groups of viruses, including over 169 RV genotypes of HRV and 116 Genotypes of EV, according to the International Committee on Taxonomy of Viruses (ICTV) [<xref rid="B19-viruses-16-01924" ref-type="bibr">19</xref>]. We detected 32 viruses of HRV-A, which belonged to 15 different genotypes, 23 HRV-C, which belonged to eight genotypes, and only three HRV-B, which belonged to three genotypes. According to different studies, RV-A and RV-C are also predominant in the world [<xref rid="B20-viruses-16-01924" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01924" ref-type="bibr">21</xref>,<xref rid="B22-viruses-16-01924" ref-type="bibr">22</xref>]. In the review of Esneau C. [<xref rid="B5-viruses-16-01924" ref-type="bibr">5</xref>], based on the analysis of studies conducted in different regions, the top 25 subtypes of rhinoviruses in Europe, Asia, and Africa were identified. In our study, RV-C41 was the most often detected (13/58), which, however, was not in the 25 highest-ranked subtypes in the Esneau C. study [<xref rid="B5-viruses-16-01924" ref-type="bibr">5</xref>].</p><p>HRV infections occur year-round; however, seasonality is characterized by a major peak of infection in the autumn/fall and a smaller one in the spring [<xref rid="B23-viruses-16-01924" ref-type="bibr">23</xref>], while EV infection peaks in summer and early autumn [<xref rid="B24-viruses-16-01924" ref-type="bibr">24</xref>]. We also could see HRV infection throughout the year, with two peaks in the autumn and spring months and the majority of cases of confirmed EV infection occurring in the fall of 2023.</p><p>Some investigators have reported that RV-C caused more serious illness compared with cases caused by RV-A and RV-B [<xref rid="B23-viruses-16-01924" ref-type="bibr">23</xref>,<xref rid="B25-viruses-16-01924" ref-type="bibr">25</xref>]. However, other studies have not found differences in the disease severity [<xref rid="B21-viruses-16-01924" ref-type="bibr">21</xref>,<xref rid="B26-viruses-16-01924" ref-type="bibr">26</xref>]. Some researchers note that low respiratory tract infection was more common in HRV-C than HRV-A illness cases [<xref rid="B25-viruses-16-01924" ref-type="bibr">25</xref>]. We did not find a statistically significant difference in the severity of the diseases due to the small number of analyzed cases, however we observed a tendency towards statistically significant differences in the presence of hypoxia and a lower proportion of upper respiratory tract diseases in children with HRV-C compared with HRV-A.</p><p>The most prevalent genotype of EV in our study was EV-D68. We detected 13 cases of EV-D68 infection, mostly in young children. All patients had low respiratory tract infection (bronchitis or pneumonia). In addition to respiratory tract infections, EV-D68 illnesses can be associated with neurologic diseases, such as acute flaccid myelitis [<xref rid="B9-viruses-16-01924" ref-type="bibr">9</xref>]. None of the patients showed neurological symptoms in our study. Phylogenetic analysis of the VP1 fragment showed that all our sequences belonged to the B3 subclade of enterovirus D68, which is most often responsible for outbreaks of respiratory diseases caused by enteroviruses [<xref rid="B27-viruses-16-01924" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01924" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01924" ref-type="bibr">29</xref>]. Intriguingly, the sequences of enterovirus D68 from Novosibirsk, Russia, are very similar to sequences of enteroviruses from different parts of the world, such as Africa and Canada. Such information indicates the possibility of transmission of enterovirus D68 between countries located at great distances. Moreover, homology is observed between strains found in one year in distant parts of the world (Novosibirsk, 2024 and Senegal, 2023). This indicates the high speed with which enterovirus D68 is able to cross continental boundaries.</p><p>In our study, we identified the first case of the EV-C105 infection in Russia in an HIV-positive two-year-old girl hospitalized with pneumonia, and it was detected in combination with Coronavirus HKU-1/OC 43. The girl had only respiratory symptoms and no neurological manifestations. Phylogenetically, the Novosibirsk strain EV-C105 was close to the strain discovered in France in 2018. The genotype C105 was discovered less than two decades ago, and there are currently only 34 sequences in NCBI GenBank. It was first identified in the Democratic Republic of the Congo in 2010 from patients with acute flaccid paralysis [<xref rid="B30-viruses-16-01924" ref-type="bibr">30</xref>]. Thus, it can be inferred that either 14 years or less have passed before the virus transferred from Africa to Europe and then to the Asian part of Russia. Nevertheless, this is a hypothesis as there are not many sequenced strains of enteroviruses, especially for this genotype, as mentioned earlier.</p><p>Phylogenetic analysis of Coxsackievirus A6 strains showed their similarity with strains from different cities of Russia (Khabarovsk, Miass) as well as other countries (China and The Netherlands). The wide geographic distribution of Coxsackievirus A6 viruses indicates the strain can travel long distances. At the same time, between 2020 and 2022, many countries introduced quarantine measures that reduced the volume of passenger and cargo shipments, which may have slowed but did not stop the spread of the virus.</p><p>The observed similarities between the detected enterovirus strains (coxsackieviruses, echovirus) in Russia may indicate related sources of infection and the ability of the strains to circulate in the population for several years. In addition, the genetic similarity of most strains to those detected in countries such as China, The Netherlands, and Kazakhstan indicates a broader circulation pattern that may include international transmission routes.</p><p>The implementation of non-pharmaceutical interventions aimed at mitigating the spread of SARS-CoV-2 led to a marked decline in the activity of many respiratory viruses. For instance, global influenza virus activity saw a substantial reduction during the early months of the pandemic, as non-pharmaceutical interventions effectively curtailed transmission routes shared with other respiratory viruses [<xref rid="B31-viruses-16-01924" ref-type="bibr">31</xref>]. RSV also experienced significant decreases in case counts across various regions, particularly affecting pediatric populations where close contact in settings like childcare facilities is common. In contrast, rhinoviruses and enteroviruses demonstrated resilience during this period. While their prevalence initially declined at the pandemic&#x02019;s onset, they quickly rebounded and maintained levels comparable to those observed in previous years [<xref rid="B32-viruses-16-01924" ref-type="bibr">32</xref>]. This resilience may be attributed to their transmission dynamics and environmental stability, which allowed them to persist even amidst stringent public health measures. Overall, the COVID-19 pandemic has reshaped our understanding of respiratory virus epidemiology. The reductions in circulation for many enveloped viruses highlight the effectiveness of control measures, while the sustained presence of rhinoviruses underscores their unique characteristics within the respiratory viral landscape. Continued surveillance and research are essential to inform future public health strategies as we navigate the ongoing impacts of these changes.</p></sec></body><back><ack><title>Acknowledgments</title><p>We kindly thank the clinicians of Novosibirsk Children&#x02019;s Municipal Clinical Hospitals &#x02116;3 and &#x02116;6 for their assistance with sample collection. </p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, O.G.K. and K.A.S.; Methodology, O.G.K., A.R.N., N.A.D., A.A.D. and K.A.S.; Software, A.R.N., N.A.D. and A.A.D.; Validation, T.A.S. and O.G.K.; Formal analysis, A.R.N., T.A.S., M.V.S., T.A.M., T.A.G., N.A.D., A.A.D. and O.G.K.; Investigation, T.A.G., T.A.M. and T.A.S.; Resources, T.A.S. and M.V.S.; Data curation, O.G.K., T.A.S. and K.A.S.; Writing&#x02014;original draft, A.R.N. and O.G.K.; Writing&#x02014;review &#x00026; editing, O.G.K., A.R.N. and K.A.S.; Visualization, A.R.N., N.A.D., A.A.D. and O.G.K.; Project administration, A.M.S.; Funding acquisition, O.G.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All aspects of the study were approved by the Committee on Biomedical Ethics of the Federal Research Center of Fundamental and Translational Medicine (protocol No. 16 on 15 June 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all patients/legal representatives involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article; further inquiries can be directed to the corresponding author. Also, the nucleotide sequences of partial VP1 have been deposited in the NCBI GenBank database (rhinoviruses: PQ539483-PQ539537, enteroviruses: PQ519611-PQ519632).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01924"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mengual-Chuli&#x000e1;</surname><given-names>B.</given-names></name>
<name><surname>Tamayo-Trujillo</surname><given-names>R.</given-names></name>
<name><surname>Mira-Iglesias</surname><given-names>A.</given-names></name>
<name><surname>Cano</surname><given-names>L.</given-names></name>
<name><surname>Garc&#x000ed;a-Esteban</surname><given-names>S.</given-names></name>
<name><surname>Ferr&#x000fa;s</surname><given-names>M.L.</given-names></name>
<name><surname>Puig-Barber&#x000e0;</surname><given-names>J.</given-names></name>
<name><surname>D&#x000ed;ez-Domingo</surname><given-names>J.</given-names></name>
<name><surname>L&#x000f3;pez-Labrador</surname><given-names>F.X.</given-names></name>
<collab>VAHNSI network</collab>
</person-group><article-title>Enterovirus D68 disease burden and epidemiology in hospital-admitted influenza-like illness, Valencia region of Spain, 2014&#x02013;2020 influenza seasons</article-title><source>J. Med. Virol.</source><year>2024</year><volume>96</volume><fpage>e29810</fpage><pub-id pub-id-type="doi">10.1002/jmv.29810</pub-id><pub-id pub-id-type="pmid">39049549</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01924"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linster</surname><given-names>M.</given-names></name>
<name><surname>Donato</surname><given-names>C.</given-names></name>
<name><surname>Mah</surname><given-names>M.G.</given-names></name>
<name><surname>Grau</surname><given-names>M.L.</given-names></name>
<name><surname>Low</surname><given-names>J.G.</given-names></name>
<name><surname>Ooi</surname><given-names>E.E.</given-names></name>
<name><surname>Su</surname><given-names>Y.C.F.</given-names></name>
<name><surname>Smith</surname><given-names>G.J.D.</given-names></name>
<name><surname>Vijaykrishna</surname><given-names>D.</given-names></name>
</person-group><article-title>Genetic diversity of respiratory enteroviruses and rhinoviruses in febrile adults, Singapore, 2007&#x02013;2013</article-title><source>Influenza Other Respir. Viruses</source><year>2020</year><volume>14</volume><fpage>67</fpage><lpage>71</lpage><!--<pub-id pub-id-type="pmcid">PMC6928033</pub-id>--><pub-id pub-id-type="doi">10.1111/irv.12662</pub-id><pub-id pub-id-type="pmid">31568667</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01924"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Royston</surname><given-names>L.</given-names></name>
<name><surname>Tapparel</surname><given-names>C.</given-names></name>
</person-group><article-title>Rhinoviruses and Respiratory Enteroviruses: Not as Simple as ABC</article-title><source>Viruses</source><year>2016</year><volume>8</volume><elocation-id>16</elocation-id><!--<pub-id pub-id-type="pmcid">PMC4728576</pub-id>--><pub-id pub-id-type="doi">10.3390/v8010016</pub-id><pub-id pub-id-type="pmid">26761027</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01924"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>M.</given-names></name>
<name><surname>Banu</surname><given-names>A.</given-names></name>
<name><surname>Jia</surname><given-names>Y.</given-names></name>
<name><surname>Chang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>An</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Circulation pattern and genetic variation of rhinovirus infection among hospitalized children on Hainan Island, before and after the dynamic zero-COVID policy, from 2021 to 2023</article-title><source>J. Med. Virol.</source><year>2024</year><volume>96</volume><fpage>e29755</fpage><pub-id pub-id-type="doi">10.1002/jmv.29755</pub-id><pub-id pub-id-type="pmid">38922896</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01924"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esneau</surname><given-names>C.</given-names></name>
<name><surname>Duff</surname><given-names>A.C.</given-names></name>
<name><surname>Bartlett</surname><given-names>N.W.</given-names></name>
</person-group><article-title>Understanding Rhinovirus Circulation and Impact on Illness</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>141</elocation-id><!--<pub-id pub-id-type="pmcid">PMC8778310</pub-id>--><pub-id pub-id-type="doi">10.3390/v14010141</pub-id><pub-id pub-id-type="pmid">35062345</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01924"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tapparel</surname><given-names>C.</given-names></name>
<name><surname>Siegrist</surname><given-names>F.</given-names></name>
<name><surname>Petty</surname><given-names>T.J.</given-names></name>
<name><surname>Kaiser</surname><given-names>L.</given-names></name>
</person-group><article-title>Picornavirus and enterovirus diversity with associated human diseases</article-title><source>Infect. Genet. Evol.</source><year>2013</year><volume>14</volume><fpage>282</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.10.016</pub-id><pub-id pub-id-type="pmid">23201849</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01924"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holm-Hansen</surname><given-names>C.C.</given-names></name>
<name><surname>Midgley</surname><given-names>S.E.</given-names></name>
<name><surname>Fischer</surname><given-names>T.K.</given-names></name>
</person-group><article-title>Global emergence of enterovirus D68: A systematic review</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><fpage>e64</fpage><lpage>e75</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00543-5</pub-id><pub-id pub-id-type="pmid">26929196</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01924"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fall</surname><given-names>A.</given-names></name>
<name><surname>Kenmoe</surname><given-names>S.</given-names></name>
<name><surname>Ebogo-Belobo</surname><given-names>J.T.</given-names></name>
<name><surname>Mbaga</surname><given-names>D.S.</given-names></name>
<name><surname>Bowo-Ngandji</surname><given-names>A.</given-names></name>
<name><surname>Foe-Essomba</surname><given-names>J.R.</given-names></name>
<name><surname>Tchatchouang</surname><given-names>S.</given-names></name>
<name><surname>Amougou Atsama</surname><given-names>M.</given-names></name>
<name><surname>Y&#x000e9;ngu&#x000e9;</surname><given-names>J.F.</given-names></name>
<name><surname>Kenfack-Momo</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Global prevalence and case fatality rate of Enterovirus D68 infections, a systematic review and meta-analysis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2022</year><volume>16</volume><elocation-id>e0010073</elocation-id><!--<pub-id pub-id-type="pmcid">PMC8824346</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pntd.0010073</pub-id><pub-id pub-id-type="pmid">35134062</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01924"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grizer</surname><given-names>C.S.</given-names></name>
<name><surname>Messacar</surname><given-names>K.</given-names></name>
<name><surname>Mattapallil</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Enterovirus-D68&#x02014;A Reemerging Non-Polio Enterovirus that Causes Severe Respiratory and Neurological Disease in Children</article-title><source>Front. Virol.</source><year>2024</year><volume>4</volume><elocation-id>1328457</elocation-id><pub-id pub-id-type="doi">10.3389/fviro.2024.1328457</pub-id><!--<pub-id pub-id-type="pmcid">PMC11378966</pub-id>--><pub-id pub-id-type="pmid">39246649</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01924"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rankin</surname><given-names>D.A.</given-names></name>
<name><surname>Spieker</surname><given-names>A.J.</given-names></name>
<name><surname>Perez</surname><given-names>A.</given-names></name>
<name><surname>Stahl</surname><given-names>A.L.</given-names></name>
<name><surname>Rahman</surname><given-names>H.K.</given-names></name>
<name><surname>Stewart</surname><given-names>L.S.</given-names></name>
<name><surname>Schuster</surname><given-names>J.E.</given-names></name>
<name><surname>Lively</surname><given-names>J.Y.</given-names></name>
<name><surname>Haddadin</surname><given-names>Z.</given-names></name>
<name><surname>Probst</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Circulation of Rhinoviruses and/or Enteroviruses in Pediatric Patients with Acute Respiratory Illness Before and During the COVID-19 Pandemic in the US</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e2254909</fpage><!--<pub-id pub-id-type="pmcid">PMC10408278</pub-id>--><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.54909</pub-id><pub-id pub-id-type="pmid">36749589</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01924"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Enterovirus Surveillance Guidelines&#x02014;Guidelines for Enterovirus Surveillance in Support of the Polio Eradication Initiative</source><publisher-name>World Health Organization Regional Office for Europe</publisher-name><publisher-loc>Copenhagen, Denmark</publisher-loc><year>2015</year></element-citation></ref><ref id="B12-viruses-16-01924"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katoh</surname><given-names>K.</given-names></name>
<name><surname>Standley</surname><given-names>D.M.</given-names></name>
</person-group><article-title>MAFFT multiple sequence alignment software version 7: Improvements in performance and usability</article-title><source>Mol. Biol. Evol.</source><year>2013</year><volume>30</volume><fpage>772</fpage><lpage>780</lpage><!--<pub-id pub-id-type="pmcid">PMC3603318</pub-id>--><pub-id pub-id-type="doi">10.1093/molbev/mst010</pub-id><pub-id pub-id-type="pmid">23329690</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01924"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trifinopoulos</surname><given-names>J.</given-names></name>
<name><surname>Nguyen</surname><given-names>L.T.</given-names></name>
<name><surname>von Haeseler</surname><given-names>A.</given-names></name>
<name><surname>Minh</surname><given-names>B.Q.</given-names></name>
</person-group><article-title>W-IQ-TREE: A fast online phylogenetic tool for maximum likelihood analysis</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>W232</fpage><lpage>W235</lpage><!--<pub-id pub-id-type="pmcid">PMC4987875</pub-id>--><pub-id pub-id-type="doi">10.1093/nar/gkw256</pub-id><pub-id pub-id-type="pmid">27084950</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01924"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minh</surname><given-names>B.Q.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.A.</given-names></name>
<name><surname>von Haeseler</surname><given-names>A.</given-names></name>
</person-group><article-title>Ultrafast approximation for phylogenetic bootstrap</article-title><source>Mol. Biol. Evol.</source><year>2013</year><volume>30</volume><fpage>1188</fpage><lpage>1195</lpage><!--<pub-id pub-id-type="pmcid">PMC3670741</pub-id>--><pub-id pub-id-type="doi">10.1093/molbev/mst024</pub-id><pub-id pub-id-type="pmid">23418397</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01924"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guindon</surname><given-names>S.</given-names></name>
<name><surname>Gascuel</surname><given-names>O.</given-names></name>
</person-group><article-title>A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood</article-title><source>Syst. Biol.</source><year>2003</year><volume>52</volume><fpage>696</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1080/10635150390235520</pub-id><pub-id pub-id-type="pmid">14530136</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01924"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letunic</surname><given-names>I.</given-names></name>
<name><surname>Bork</surname><given-names>P.</given-names></name>
</person-group><article-title>Interactive Tree of Life (iTOL) v6: Recent updates to the phylogenetic tree display and annotation tool</article-title><source>Nucleic Acids Res.</source><year>2024</year><volume>52</volume><fpage>W78</fpage><lpage>W82</lpage><!--<pub-id pub-id-type="pmcid">PMC11223838</pub-id>--><pub-id pub-id-type="doi">10.1093/nar/gkae268</pub-id><pub-id pub-id-type="pmid">38613393</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01924"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fine</surname><given-names>J.</given-names></name>
<name><surname>Bray-Aschenbrenner</surname><given-names>A.</given-names></name>
<name><surname>Williams</surname><given-names>H.</given-names></name>
<name><surname>Buchanan</surname><given-names>P.</given-names></name>
<name><surname>Werner</surname><given-names>J.</given-names></name>
</person-group><article-title>The Resource Burden of Infections With Rhinovirus/Enterovirus, Influenza, and Respiratory Syncytial Virus in Children</article-title><source>Clin. Pediatr.</source><year>2019</year><volume>58</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1177/0009922818809483</pub-id><pub-id pub-id-type="pmid">30387696</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01924"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Louie</surname><given-names>J.K.</given-names></name>
<name><surname>Roy-Burman</surname><given-names>A.</given-names></name>
<name><surname>Guardia-Labar</surname><given-names>L.</given-names></name>
<name><surname>Boston</surname><given-names>E.J.</given-names></name>
<name><surname>Kiang</surname><given-names>D.</given-names></name>
<name><surname>Padilla</surname><given-names>T.</given-names></name>
<name><surname>Yagi</surname><given-names>S.</given-names></name>
<name><surname>Messenger</surname><given-names>S.</given-names></name>
<name><surname>Petru</surname><given-names>A.M.</given-names></name>
<name><surname>Glaser</surname><given-names>C.A.</given-names></name>
<etal/>
</person-group><article-title>Rhinovirus associated with severe lower respiratory tract infections in children</article-title><source>Pediatr. Infect. Dis. J.</source><year>2009</year><volume>28</volume><fpage>337</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e31818ffc1b</pub-id><pub-id pub-id-type="pmid">19258921</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01924"><label>19.</label><element-citation publication-type="webpage"><article-title>Current ICTV Taxonomy Release</article-title><comment>Available online: <ext-link xlink:href="https://ictv.global/taxonomy/" ext-link-type="uri">https://ictv.global/taxonomy/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-28">(accessed on 28 October 2024)</date-in-citation></element-citation></ref><ref id="B20-viruses-16-01924"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giardina</surname><given-names>F.A.M.</given-names></name>
<name><surname>Piralla</surname><given-names>A.</given-names></name>
<name><surname>Ferrari</surname><given-names>G.</given-names></name>
<name><surname>Zavaglio</surname><given-names>F.</given-names></name>
<name><surname>Cassaniti</surname><given-names>I.</given-names></name>
<name><surname>Baldanti</surname><given-names>F.</given-names></name>
</person-group><article-title>Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><elocation-id>755</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9030097</pub-id>--><pub-id pub-id-type="doi">10.3390/microorganisms10040755</pub-id><pub-id pub-id-type="pmid">35456806</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01924"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuypers</surname><given-names>J.</given-names></name>
<name><surname>Perchetti</surname><given-names>G.A.</given-names></name>
<name><surname>Chu</surname><given-names>H.Y.</given-names></name>
<name><surname>Newman</surname><given-names>K.L.</given-names></name>
<name><surname>Katz</surname><given-names>J.</given-names></name>
<name><surname>Khatry</surname><given-names>S.K.</given-names></name>
<name><surname>LeClerq</surname><given-names>S.C.</given-names></name>
<name><surname>Jerome</surname><given-names>K.R.</given-names></name>
<name><surname>Tielsch</surname><given-names>J.M.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Phylogenetic characterization of rhinoviruses from infants in Sarlahi, Nepal</article-title><source>J. Med. Virol.</source><year>2019</year><volume>91</volume><fpage>2108</fpage><lpage>2116</lpage><!--<pub-id pub-id-type="pmcid">PMC6800797</pub-id>--><pub-id pub-id-type="doi">10.1002/jmv.25563</pub-id><pub-id pub-id-type="pmid">31389049</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01924"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgieva</surname><given-names>I.</given-names></name>
<name><surname>Stoyanova</surname><given-names>A.</given-names></name>
<name><surname>Angelova</surname><given-names>S.</given-names></name>
<name><surname>Korsun</surname><given-names>N.</given-names></name>
<name><surname>Stoitsova</surname><given-names>S.</given-names></name>
<name><surname>Nikolaeva-Glomb</surname><given-names>L.</given-names></name>
</person-group><article-title>Rhinovirus Genotypes Circulating in Bulgaria, 2018&#x02013;2021</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1608</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10385483</pub-id>--><pub-id pub-id-type="doi">10.3390/v15071608</pub-id><pub-id pub-id-type="pmid">37515294</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01924"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bizzintino</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>W.M.</given-names></name>
<name><surname>Laing</surname><given-names>I.A.</given-names></name>
<name><surname>Vang</surname><given-names>F.</given-names></name>
<name><surname>Pappas</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Martin</surname><given-names>A.C.</given-names></name>
<name><surname>Khoo</surname><given-names>S.K.</given-names></name>
<name><surname>Cox</surname><given-names>D.W.</given-names></name>
<name><surname>Geelhoed</surname><given-names>G.C.</given-names></name>
<etal/>
</person-group><article-title>Association between human rhinovirus C and severity of acute asthma in children</article-title><source>Eur. Respir. J.</source><year>2011</year><volume>37</volume><fpage>1037</fpage><lpage>1042</lpage><!--<pub-id pub-id-type="pmcid">PMC3024467</pub-id>--><pub-id pub-id-type="doi">10.1183/09031936.00092410</pub-id><pub-id pub-id-type="pmid">20693244</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01924"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baertl</surname><given-names>S.</given-names></name>
<name><surname>Pietsch</surname><given-names>C.</given-names></name>
<name><surname>Maier</surname><given-names>M.</given-names></name>
<name><surname>H&#x000f6;nemann</surname><given-names>M.</given-names></name>
<name><surname>Bergs</surname><given-names>S.</given-names></name>
<name><surname>Liebert</surname><given-names>U.G.</given-names></name>
</person-group><article-title>Enteroviruses in Respiratory Samples from Paediatric Patients of a Tertiary Care Hospital in Germany</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>882</elocation-id><pub-id pub-id-type="doi">10.3390/v13050882</pub-id><pub-id pub-id-type="pmid">34064852</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01924"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>E.K.</given-names></name>
<name><surname>Kuypers</surname><given-names>J.</given-names></name>
<name><surname>Chu</surname><given-names>H.Y.</given-names></name>
<name><surname>Lacombe</surname><given-names>K.</given-names></name>
<name><surname>Qin</surname><given-names>X.</given-names></name>
<name><surname>Strelitz</surname><given-names>B.</given-names></name>
<name><surname>Bradford</surname><given-names>M.</given-names></name>
<name><surname>Jones</surname><given-names>C.</given-names></name>
<name><surname>Klein</surname><given-names>E.J.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Molecular epidemiology of human rhinovirus infections in the pediatric emergency department</article-title><source>J. Clin. Virol.</source><year>2015</year><volume>62</volume><fpage>25</fpage><lpage>31</lpage><!--<pub-id pub-id-type="pmcid">PMC4403738</pub-id>--><pub-id pub-id-type="doi">10.1016/j.jcv.2014.11.006</pub-id><pub-id pub-id-type="pmid">25542466</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01924"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCulloch</surname><given-names>D.J.</given-names></name>
<name><surname>Sears</surname><given-names>M.H.</given-names></name>
<name><surname>Jacob</surname><given-names>J.T.</given-names></name>
<name><surname>Lyon</surname><given-names>G.M.</given-names></name>
<name><surname>Burd</surname><given-names>E.M.</given-names></name>
<name><surname>Caliendo</surname><given-names>A.M.</given-names></name>
<name><surname>Hill</surname><given-names>C.E.</given-names></name>
<name><surname>Nix</surname><given-names>W.A.</given-names></name>
<name><surname>Oberste</surname><given-names>M.S.</given-names></name>
<name><surname>Kraft</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Severity of rhinovirus infection in hospitalized adults is unrelated to genotype</article-title><source>Am. J. Clin. Pathol.</source><year>2014</year><volume>142</volume><fpage>165</fpage><lpage>172</lpage><!--<pub-id pub-id-type="pmcid">PMC4332627</pub-id>--><pub-id pub-id-type="doi">10.1309/AJCPHIKRJC67AAZJ</pub-id><pub-id pub-id-type="pmid">25015856</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01924"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Gu</surname><given-names>D.Y.</given-names></name>
<name><surname>Meng</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Y.Q.</given-names></name>
<name><surname>Yao</surname><given-names>X.J.</given-names></name>
<name><surname>Zhang</surname><given-names>H.L.</given-names></name>
<name><surname>Cheng</surname><given-names>J.Q.</given-names></name>
<name><surname>Ma</surname><given-names>H.W.</given-names></name>
<etal/>
</person-group><article-title>Identification and Whole-Genome Sequencing of Four Enterovirus D68 Strains in Southern China in Late 2015</article-title><source>Genome Announc.</source><year>2016</year><volume>4</volume><fpage>e01014-16</fpage><!--<pub-id pub-id-type="pmcid">PMC5034141</pub-id>--><pub-id pub-id-type="doi">10.1128/genomeA.01014-16</pub-id><pub-id pub-id-type="pmid">27660790</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01924"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Yin</surname><given-names>C.</given-names></name>
<name><surname>Zhuge</surname><given-names>J.</given-names></name>
<name><surname>Farooq</surname><given-names>T.</given-names></name>
<name><surname>Yoon</surname><given-names>E.C.</given-names></name>
<name><surname>Nolan</surname><given-names>S.M.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Fallon</surname><given-names>J.T.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
</person-group><article-title>Complete Genome Sequences of Nine Enterovirus D68 Strains from Patients of the Lower Hudson Valley, New York, <bold>2016</bold></article-title><source>Genome Announc.</source><year>2016</year><volume>4</volume><fpage>e01394-16</fpage><!--<pub-id pub-id-type="pmcid">PMC5159578</pub-id>--><pub-id pub-id-type="doi">10.1128/genomeA.01394-16</pub-id><pub-id pub-id-type="pmid">27979945</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01924"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piralla</surname><given-names>A.</given-names></name>
<name><surname>Principi</surname><given-names>N.</given-names></name>
<name><surname>Ruggiero</surname><given-names>L.</given-names></name>
<name><surname>Girello</surname><given-names>A.</given-names></name>
<name><surname>Giardina</surname><given-names>F.</given-names></name>
<name><surname>De Sando</surname><given-names>E.</given-names></name>
<name><surname>Caimmi</surname><given-names>S.</given-names></name>
<name><surname>Bianchini</surname><given-names>S.</given-names></name>
<name><surname>Marseglia</surname><given-names>G.L.</given-names></name>
<name><surname>Lunghi</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Enterovirus-D68 (EV-D68) in pediatric patients with respiratory infection: The circulation of a new B3 clade in Italy</article-title><source>J. Clin. Virol.</source><year>2018</year><volume>99&#x02013;100</volume><fpage>91</fpage><lpage>96</lpage><!--<pub-id pub-id-type="pmcid">PMC7185653</pub-id>--><pub-id pub-id-type="doi">10.1016/j.jcv.2018.01.005</pub-id><pub-id pub-id-type="pmid">29396353</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01924"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grard</surname><given-names>G.</given-names></name>
<name><surname>Drexler</surname><given-names>J.F.</given-names></name>
<name><surname>Lekana-Douki</surname><given-names>S.</given-names></name>
<name><surname>Caron</surname><given-names>M.</given-names></name>
<name><surname>Lukashev</surname><given-names>A.</given-names></name>
<name><surname>Nkoghe</surname><given-names>D.</given-names></name>
<name><surname>Gonzalez</surname><given-names>J.P.</given-names></name>
<name><surname>Drosten</surname><given-names>C.</given-names></name>
<name><surname>Leroy</surname><given-names>E.</given-names></name>
</person-group><article-title>Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October&#x02013;November 2010</article-title><source>Eurosurveillance</source><year>2010</year><volume>15</volume><fpage>19723</fpage><pub-id pub-id-type="doi">10.2807/ese.15.47.19723-en</pub-id><pub-id pub-id-type="pmid">21144443</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01924"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chow</surname><given-names>E.J.</given-names></name>
<name><surname>Uyeki</surname><given-names>T.M.</given-names></name>
<name><surname>Chu</surname><given-names>H.Y.</given-names></name>
</person-group><article-title>The effects of the COVID-19 pandemic on community respiratory virus activity</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>195</fpage><lpage>210</lpage><!--<pub-id pub-id-type="pmcid">PMC9574826</pub-id>--><pub-id pub-id-type="doi">10.1038/s41579-022-00807-9</pub-id><pub-id pub-id-type="pmid">36253478</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01924"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taktak</surname><given-names>A.</given-names></name>
<name><surname>Smaoui</surname><given-names>F.</given-names></name>
<name><surname>Chtourou</surname><given-names>A.</given-names></name>
<name><surname>Ma&#x000e2;loul</surname><given-names>M.</given-names></name>
<name><surname>Karray-Hakim</surname><given-names>H.</given-names></name>
<name><surname>Hammami</surname><given-names>A.</given-names></name>
<name><surname>Fki-Berrajah</surname><given-names>L.</given-names></name>
<name><surname>Gargouri</surname><given-names>S.</given-names></name>
</person-group><article-title>Significant impact of COVID-19 pandemic on the circulation of respiratory viruses in Tunisia, 2020&#x02013;2021</article-title><source>Clin. Epidemiol. Glob. Health</source><year>2023</year><volume>21</volume><fpage>101306</fpage><!--<pub-id pub-id-type="pmcid">PMC10132842</pub-id>--><pub-id pub-id-type="doi">10.1016/j.cegh.2023.101306</pub-id><pub-id pub-id-type="pmid">37131909</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01924-f001"><label>Figure 1</label><caption><p>PCR detection rate of respiratory viruses in different age groups. Asterisks indicate differences between the 7&#x02013;17&#x02013;year age group and other age groups in the presence of respiratory viruses (**, AR = &#x02212;8.96, <italic toggle="yes">p</italic> &#x0003c; 0.001) and co-infection (*, AR = &#x02212;4.99, <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="viruses-16-01924-g001" position="float"/></fig><fig position="float" id="viruses-16-01924-f002"><label>Figure 2</label><caption><p>Age distribution of respiratory viruses in hospitalized children in 2023&#x02013;2024. The prevalence of respiratory viruses significantly varies among age groups (Chi2 = 193.24, <italic toggle="yes">p</italic> &#x0003c; 0.001). Blue asterisks indicate negative AR, suggesting lower-than-expected frequencies, while red asterisks represent positive AR, indicating higher-than-expected frequencies, both with <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="viruses-16-01924-g002" position="float"/></fig><fig position="float" id="viruses-16-01924-f003"><label>Figure 3</label><caption><p>Seasonal distribution of respiratory viruses in 2023&#x02013;2024.</p></caption><graphic xlink:href="viruses-16-01924-g003" position="float"/></fig><fig position="float" id="viruses-16-01924-f004"><label>Figure 4</label><caption><p>The bar chart shows the standardized residuals obtained from the chi-square test. These residuals serve as a measure of how much each category deviates from what would be anticipated under the null hypothesis, highlighting significant disparities in virus distribution across seasons. The red dotted line indicates the critical value of |1.96|, representing the 95% confidence threshold.</p></caption><graphic xlink:href="viruses-16-01924-g004" position="float"/></fig><fig position="float" id="viruses-16-01924-f005"><label>Figure 5</label><caption><p>The bar chart shows the standardized residuals obtained from the chi-square test. These residuals help estimate how much the observed frequencies differ from the expected ones, which allows us to identify statistically significant deviations in the distribution of symptoms. The red dotted line indicates the threshold |1.96|, which corresponds to the 95% significance level.</p></caption><graphic xlink:href="viruses-16-01924-g005" position="float"/></fig><fig position="float" id="viruses-16-01924-f006"><label>Figure 6</label><caption><p>Heatmap showing the occurrence of EV or RV among different months.</p></caption><graphic xlink:href="viruses-16-01924-g006" position="float"/></fig><fig position="float" id="viruses-16-01924-f007"><label>Figure 7</label><caption><p>The phylogenetic tree constructed from partial VP1 nucleotide sequences of rhinoviruses (161 sequences). The analysis was inferred using the Maximum Likelihood method (substitution model: GTR + F + I + G4 + R). Reference strains for each species are shown with a blue circle; current study strains (n = 56) are shown in red. Colored bars indicate the genotype. Ultrafast bootstrap &#x0003e; 70% and SH-aLRT &#x0003e; 60% support values (n = 1000) are marked on the branches with purple circles, the size of which reflects the level of support.</p></caption><graphic xlink:href="viruses-16-01924-g007" position="float"/></fig><fig position="float" id="viruses-16-01924-f008"><label>Figure 8</label><caption><p>The phylogenetic tree constructed from partial VP1 nucleotide sequences of enteroviruses (61 sequences). The analysis was inferred using the Maximum Likelihood method (substitution model: K2P + G4 + R). Reference strains for each species are shown with a blue circle; current study strains (n = 22) are shown in red. Colored bars indicate the genotype. Ultrafast bootstrap &#x0003e; 70% and SH-aLRT &#x0003e; 60% support values (n = 1000) are marked on the branches with purple circles, the size of which reflects the level of support.</p></caption><graphic xlink:href="viruses-16-01924-g008" position="float"/></fig><fig position="float" id="viruses-16-01924-f009"><label>Figure 9</label><caption><p>The phylogenetic tree constructed from partial VP1 nucleotide sequences of enteroviruses D68 (139 sequences). The tree includes GenBank sequences belonging to known clades. The analysis was inferred using the Maximum Likelihood method (substitution model: TN + F + G4 + R). Reference strain for enterovirus D68 is shown with a blue circle; current study strains (n = 12) are shown in red. Ultrafast bootstrap &#x0003e; 70% and SH-aLRT &#x0003e; 60% support values (n = 1000) are marked on the branches with purple circles, the size of which reflects the level of support.</p></caption><graphic xlink:href="viruses-16-01924-g009" position="float"/></fig><table-wrap position="float" id="viruses-16-01924-t001"><object-id pub-id-type="pii">viruses-16-01924-t001_Table 1</object-id><label>Table 1</label><caption><p>Primers used for cDNA synthesis and PCR amplification (according to WHO recommendations) [<xref rid="B11-viruses-16-01924" ref-type="bibr">11</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Step</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">cDNA (RT) primers</td><td align="center" valign="middle" rowspan="1" colspan="1">AN32</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032; GTY TGC CA 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AN33</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032; GAY TGC CA 3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AN34</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032; CCR TCR TA 3&#x02032;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AN35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02032; RCT YTG CCA 3&#x02032;</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PCR 1 primers</td><td align="center" valign="middle" rowspan="1" colspan="1">SO224 (forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032; GCI ATG YTI GGI ACI CAY RT 3&#x02032;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SO222 (reverse)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02032; C ICC IGG IGG IAY RWA CAT 3&#x02032;</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">snPCR 2 primers</td><td align="center" valign="middle" rowspan="1" colspan="1">AN89 (forward)</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02032; CCA GCA CTG ACA GCA GYN GAR AYN GG 3&#x02032;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AN88 (reverse)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02032; TAC TGG ACC ACC TGG NGG NAY RWA CAT 3&#x02032; </td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-16-01924-t002"><object-id pub-id-type="pii">viruses-16-01924-t002_Table 2</object-id><label>Table 2</label><caption><p>Demographic characteristics of included patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Age</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sex</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;12 months</td><td align="center" valign="middle" rowspan="1" colspan="1">372<break/>(18.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">295<break/>(14.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">667<break/>(33.5%)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1&#x02013;2 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">318<break/>(15.9%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">229<break/>(11.5%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">547<break/>(27.4%)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">3&#x02013;6 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">213<break/>(10.7%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">187<break/>(9.4%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">400<break/>(20.1%)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">7&#x02013;17 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">195<break/>(9.8%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">183<break/>(9.2%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">378<break/>(19.0%)</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1098<break/>(55.1%)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">894<break/>(44.9%)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1992<break/>(100%)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: the percentage is calculated from the total number of collected samples.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01924-t003"><object-id pub-id-type="pii">viruses-16-01924-t003_Table 3</object-id><label>Table 3</label><caption><p>Distribution of HRV/EV among different age groups. Absolute, relative frequencies with 95% CI and relative risk of HRV/EV infection are indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Presence of EV/HRV</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Risk Ratio of EV/HRV Infection, 95%CI</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">0 years (n = 667)</td><td align="center" valign="middle" rowspan="1" colspan="1">89,<break/>13.34% [10.97&#x02013;16.14]</td><td align="center" valign="middle" rowspan="1" colspan="1">RR = 1.35 [1.05&#x02013;1.74] *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#x02013;2 years (n = 547)</td><td align="center" valign="middle" rowspan="1" colspan="1">64,<break/>11.70% [9.27&#x02013;14.67]</td><td align="center" valign="middle" rowspan="1" colspan="1">RR = 1.08 [0.82&#x02013;1.43]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3&#x02013;6 years (n = 400)</td><td align="center" valign="middle" rowspan="1" colspan="1">41,<break/>10.25% [7.65&#x02013;13.61]</td><td align="center" valign="middle" rowspan="1" colspan="1">RR = 0.91 [0.66&#x02013;1.26]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7&#x02013;17 years (n = 378)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,<break/>6.88% [4.74&#x02013;9.89]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RR = 0.57 [0.39&#x02013;0.85] *</td></tr></tbody></table><table-wrap-foot><fn><p>*&#x02014;indicates statistical significance.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01924-t004"><object-id pub-id-type="pii">viruses-16-01924-t004_Table 4</object-id><label>Table 4</label><caption><p>Distribution of symptoms among the most common respiratory viruses and enteroviruses/rhinoviruses. Absolute, relative frequencies, and 95% CI are indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HRV/EV<break/>(n = 220)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HInfV<break/>(n = 178)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RSV<break/>(n = 306)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comparison</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fever</td><td align="center" valign="middle" rowspan="1" colspan="1">161,<break/>73.18% [66.81&#x02013;78.91]</td><td align="center" valign="middle" rowspan="1" colspan="1">161,<break/>90.45% [85.15&#x02013;94.34]</td><td align="center" valign="middle" rowspan="1" colspan="1">231,<break/>75.49% [70.27&#x02013;80.21]</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chi<sup>2</sup> = 23.75; <italic toggle="yes">p</italic> = 0.020 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malaise</td><td align="center" valign="middle" rowspan="1" colspan="1">61,<break/>27.73% [21.92&#x02013;34.14]</td><td align="center" valign="middle" rowspan="1" colspan="1">80,<break/>44.94% [37.49&#x02013;52.56]</td><td align="center" valign="middle" rowspan="1" colspan="1">74,<break/>24.18% [19.49&#x02013;29.38]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Headache</td><td align="center" valign="middle" rowspan="1" colspan="1">1,<break/>0.45% [0.12&#x02013;0.25]</td><td align="center" valign="middle" rowspan="1" colspan="1">3,<break/>1.69% [0.35&#x02013;4.85]</td><td align="center" valign="middle" rowspan="1" colspan="1">1,<break/>0.33% [0&#x02013;1.81]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cough</td><td align="center" valign="middle" rowspan="1" colspan="1">156,<break/>70.91% [64.43&#x02013;76.82]</td><td align="center" valign="middle" rowspan="1" colspan="1">151,<break/>84.83% [78.70&#x02013;89.76]</td><td align="center" valign="middle" rowspan="1" colspan="1">232,<break/>75.82% [70.62&#x02013;80.51]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sore throat</td><td align="center" valign="middle" rowspan="1" colspan="1">8,<break/>3.64% [1.58&#x02013;7.04]</td><td align="center" valign="middle" rowspan="1" colspan="1">8,<break/>4.49% [1.96&#x02013;8.66]</td><td align="center" valign="middle" rowspan="1" colspan="1">7,<break/>2.29% [0.92&#x02013;4.66]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dyspnea</td><td align="center" valign="middle" rowspan="1" colspan="1">70,<break/>31.82% [25.72&#x02013;38.42]</td><td align="center" valign="middle" rowspan="1" colspan="1">62,<break/>34.83% [27.86&#x02013;42.32]</td><td align="center" valign="middle" rowspan="1" colspan="1">123,<break/>40.20% [34.66&#x02013;45.93]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal congestion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45,<break/>20.45% [15.33&#x02013;26.40]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50,<break/>28.09% [21.62&#x02013;35.30]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41,<break/>13.40% [9.79&#x02013;17.73]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median Temperature, &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.3 (37.8&#x02013;38.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.4 (39.0&#x02013;39.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.6 (38.0&#x02013;39.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H = 137.9, <italic toggle="yes">p</italic> &#x0003c; 0.001 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypoxia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70,<break/>31.82% [26.02&#x02013;38.24]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58,<break/>32.58% [26.13&#x02013;39.77]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131,<break/>42.81% [37.39&#x02013;48.41]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H = 8.5, <italic toggle="yes">p</italic> = 0.015 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7,<break/>3.18% [1.55&#x02013;6.42]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8,<break/>4.49% [2.30&#x02013;8.62]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5,<break/>1.63% [0.70&#x02013;3.77]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H = 3.5, <italic toggle="yes">p</italic> = 0.177</td></tr></tbody></table><table-wrap-foot><fn><p>*&#x02014;indicates statistical significance.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01924-t005"><object-id pub-id-type="pii">viruses-16-01924-t005_Table 5</object-id><label>Table 5</label><caption><p>HRV/EV genotypes distribution.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genotypes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Samples</th></tr></thead><tbody><tr><td rowspan="15" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rhinovirus A</td><td align="center" valign="middle" rowspan="1" colspan="1">RV-A12</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A15</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A22</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A29</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A38</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A40</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A53</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A54</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A55</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A56</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A58</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A73</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A75</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-A82</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RV-A106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rhinovirus B</td><td align="center" valign="middle" rowspan="1" colspan="1">RV-B6</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-B52</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RV-B103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rhinovirus C</td><td align="center" valign="middle" rowspan="1" colspan="1">RV-C7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-C10</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-C16</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-C31</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-C36</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-C40</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RV-C41</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RV-C45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Enterovirus A</td><td align="center" valign="middle" rowspan="1" colspan="1">CV A2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV A6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Enterovirus B</td><td align="center" valign="middle" rowspan="1" colspan="1">CV B5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">E5</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterovirus C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C105</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterovirus D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 species</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 genotypes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86 viruses</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-16-01924-t006"><object-id pub-id-type="pii">viruses-16-01924-t006_Table 6</object-id><label>Table 6</label><caption><p>Distribution of the characteristics of children under study with HRV A and HRV C. Absolute and relative frequencies with 95% CI are indicated for qualitative variables, and medians with interquartile range are indicated for quantitative variables.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HRV A<break/>(n = 32)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HRV C<break/>(n = 23)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comparison</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex:</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">U = 348.5; <italic toggle="yes">p</italic> = 0.789</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female (n = 27)</td><td align="center" valign="middle" rowspan="1" colspan="1">17,<break/>53.13% [36.45&#x02013;69.13]</td><td align="center" valign="middle" rowspan="1" colspan="1">11,<break/>47.83% [29.24&#x02013;67.04]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male (n = 28)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,<break/>46.88% [30.87&#x02013;63.55]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,<break/>52.17% [32.96&#x02013;70.76]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median age, years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0&#x02013;3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1&#x02013;5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U = 270.5; <italic toggle="yes">p</italic> = 0.090</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Symptoms:</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chi<sup>2</sup> = 3.45; <italic toggle="yes">p</italic> = 0.644</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fever</td><td align="center" valign="middle" rowspan="1" colspan="1">31,<break/>96.88% [83.78&#x02013;99.92]</td><td align="center" valign="middle" rowspan="1" colspan="1">22,<break/>95.65% [78.05&#x02013;99.89]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malaise</td><td align="center" valign="middle" rowspan="1" colspan="1">14,<break/>43.75% [26.36&#x02013;62.34]</td><td align="center" valign="middle" rowspan="1" colspan="1">15,<break/>65.22% [42.73&#x02013;83.62]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Headache</td><td align="center" valign="middle" rowspan="1" colspan="1">0,<break/>0% [0&#x02013;10.9]</td><td align="center" valign="middle" rowspan="1" colspan="1">0,<break/>0% [0&#x02013;14.8]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cough</td><td align="center" valign="middle" rowspan="1" colspan="1">32,<break/>100% [89.11&#x02013;100]</td><td align="center" valign="middle" rowspan="1" colspan="1">21,<break/>91.30% [71.96&#x02013;98.93]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sore throat</td><td align="center" valign="middle" rowspan="1" colspan="1">1,<break/>3.13% [0.08&#x02013;16.22]</td><td align="center" valign="middle" rowspan="1" colspan="1">3,<break/>13.04% [2.78&#x02013;33.59]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dyspnea</td><td align="center" valign="middle" rowspan="1" colspan="1">14,<break/>43.75% [26.36&#x02013;62.34]</td><td align="center" valign="middle" rowspan="1" colspan="1">15,<break/>65.22% [42.73&#x02013;83.62]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal congestion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7,<break/>21.88% [9.28&#x02013;39.97]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5,<break/>21.74% [7.46&#x02013;43.70]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median Temperature, &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.1 (37.4&#x02013;38.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.0 (37.4&#x02013;38.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U = 368.0; <italic toggle="yes">p</italic> &#x0003e; 0.999</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypoxia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8,<break/>25.00% [13.25&#x02013;42.11]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,<break/>52.17% [32.96&#x02013;70.76]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U = 268.0, <italic toggle="yes">p</italic> = 0.050</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis:</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chi<sup>2</sup> = 5,27; <italic toggle="yes">p</italic> = 0.076</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Upper respiratory tract diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">9,<break/>28.13% [15.57&#x02013;45.38]</td><td align="center" valign="middle" rowspan="1" colspan="1">1,<break/>4.35% [0.22&#x02013;20.99]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bronchitis</td><td align="center" valign="middle" rowspan="1" colspan="1">16,<break/>50.00% [33.63&#x02013;66.37]</td><td align="center" valign="middle" rowspan="1" colspan="1">14,<break/>60.87% [40.79&#x02013;77.84]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7,<break/>21.88% [11.02&#x02013;38.76]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8,<break/>34.78% [18.81&#x02013;55.11]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,<break/>6.25% [1.11&#x02013;20.15]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,<break/>4.35% [0.22&#x02013;20.99]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U = 361.0, <italic toggle="yes">p</italic> &#x0003e; 0.999</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-16-01924-t007"><object-id pub-id-type="pii">viruses-16-01924-t007_Table 7</object-id><label>Table 7</label><caption><p>Clinical characteristics of EV-D68 infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EV-D68<break/>(n = 13)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median age, months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (1&#x02013;96)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Symptoms:</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fever</td><td align="center" valign="middle" rowspan="1" colspan="1">13,<break/>100% [75.29&#x02013;100]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malaise</td><td align="center" valign="middle" rowspan="1" colspan="1">9,<break/>69.23% [38.57&#x02013;90.91]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Headache</td><td align="center" valign="middle" rowspan="1" colspan="1">1,<break/>7.69% [0.19&#x02013;36.03]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cough</td><td align="center" valign="middle" rowspan="1" colspan="1">10,<break/>76.92% [46.19&#x02013;94.96]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sore throat</td><td align="center" valign="middle" rowspan="1" colspan="1">2,<break/>15.38% [1.92&#x02013;45.45]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dyspnea</td><td align="center" valign="middle" rowspan="1" colspan="1">9,<break/>69.23% [38.57&#x02013;90.91]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nasal congestion</td><td align="center" valign="middle" rowspan="1" colspan="1">2,<break/>15.38% [1.92&#x02013;45.45]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0,<break/>0% [0&#x02013;24.71]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median Temperature, &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.3 (37.0&#x02013;39.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypoxia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6,<break/>46.15% [19.22&#x02013;74.87]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0,<break/>0% [0&#x02013;24.71]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis:</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Upper respiratory tract diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">0,<break/>0% [0&#x02013;24.71]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bronchitis</td><td align="center" valign="middle" rowspan="1" colspan="1">8,<break/>61.54% [31.58&#x02013;86.14]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5,<break/>38.46% [13.86&#x02013;68.42]</td></tr></tbody></table></table-wrap></floats-group></article>